Skip to content

Released Nov 12, 2024, after the close

10-Q filed Nov 12, 2024, 43 days after period end · 0000950170-24-125317

Q3 2024 · 10-Q
Revenue$3.07M+58.1% vs Q3 2023−54.6% vs Q2 2024
Net Income-$47.68MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.40N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$52,377,000N/M
Operating Cash Flowderived-$29,419,000N/M
Free Cash Flowderived-$29,914,000N/M
Margins · derived
Operating margin-1703.9%+933.9 pt vs Q3 2023
Net margin-1551.0%+772.6 pt vs Q3 2023

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue$3.07M$1.94M$14.98M$14.23M
Net Income-$47.68M-$45.17M-$83.56M-$43.31M
EPS Diluted-$0.40-$0.46-$0.86-$0.45

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR